Hikal Limited specializes in the manufacture of pharmaceutical ingredients, active pharma intermediates, crop protection products, and engages in contract research. They focus on strengthening global partnerships and operational scales.

In Q2 FY26, Hikal reported consolidated revenue of ₹319 crore with challenges linked to deferred pharmaceutical sales post-FDA audit and CAPA implementation. Recovery is anticipated in the following quarters.

Their crop protection and animal health segments are investing in product development and ramping up pre-commercial volumes, showing potential for future growth.

Strategic diversification into personal care and specialty chemicals through new product lines like HiZenn and HiFend exhibits initiatives in entering high-potential markets.